ストックスクリーナーアプリを入手
14.48
0.42%
0.06
前日終値:
$14.42
開ける：
$14.42
24時間の取引高:
383.51K
Relative Volume:
0.73
時価総額：
$588.11M
収益：
-
当期純損益:
$-168.05M
株価収益率:
-2.8226
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
+5.46%
1か月 パフォーマンス:
+1.61%
6か月 パフォーマンス:
+40.31%
1年 パフォーマンス:
-68.55%
1日の値動き範囲:
$14.13
$14.53
1週間の範囲:
$13.28
$14.67
52週間の値動き範囲:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
14.48 | 585.67M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Is Keros Therapeutics Inc. stock trending bullish2025 Winners & Losers & Target Return Focused Picks - thegnnews.com
Keros Therapeutics Inc. Breaks Below Key Support LevelJuly 2025 Levels & Safe Entry Point Alerts - sundaytimes.kr
Leerink Partnrs Has Negative Estimate for KROS Q3 Earnings - MarketBeat
Q3 EPS Estimate for Keros Therapeutics Lowered by Analyst - MarketBeat
Technical Bounce Expected in Keros Therapeutics Inc. Next Week2025 Year in Review & Community Consensus Picks - thegnnews.com
Keros Therapeutics Reports Strong Revenue Growth - TipRanks
XTX Topco Ltd Invests $490,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright - MarketBeat
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright - Investing.com Canada
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics - TipRanks
Keros prioritizes KER-065, pulls plug on cibotercept - The Pharma Letter
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks - TipRanks
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15 - 富途牛牛
Keros Therapeutics to discontinue cibotercept, announces COO departure - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Holdings Raised by Federated Hermes Inc. - MarketBeat
Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Keros Therapeutics Announces Strategic Realignment and Leadership Changes - TipRanks
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Keros discontinues cibotercept development, announces leadership changes By Investing.com - Investing.com South Africa
Keros discontinues cibotercept development, announces leadership changes - Investing.com
Keros Therapeutics Announces Discontinuation of Cibotercept Development and Leadership Changes for Strategic Realignment - Quiver Quantitative
Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches - Stock Titan
Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire
Is it the right time to buy Keros Therapeutics Inc. stockGet timely alerts on top market movers - Jammu Links News
Published on: 2025-08-03 17:03:57 - Jammu Links News
Keros Therapeutics Inc. Stock Analysis and ForecastCapitalize on momentum-driven investment opportunities - Jammu Links News
How does Keros Therapeutics Inc. compare to its industry peersBuild wealth faster with consistent investment plans - Jammu Links News
What are analysts’ price targets for Keros Therapeutics Inc. in the next 12 monthsAchieve breakthrough profits with expert advice - Jammu Links News
What are Keros Therapeutics Inc. company’s key revenue driversUnlock exclusive stock market forecasts - Jammu Links News
What are the technical indicators suggesting about Keros Therapeutics Inc.Unlock powerful portfolio optimization tools - Jammu Links News
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Price Target from Analysts - MarketBeat
What catalysts could drive Keros Therapeutics Inc. stock higher in 2025Unlock powerful portfolio management tools - jammulinksnews.com
How strong is Keros Therapeutics Inc. company’s balance sheetGain the edge with real-time market data - Jammu Links News
Is Keros Therapeutics Inc. stock overvalued or undervaluedExceptional market performance - Jammu Links News
How volatile is Keros Therapeutics Inc. stock compared to the marketRapid wealth creation - Jammu Links News
Why is Keros Therapeutics Inc. stock attracting strong analyst attentionPowerful market insights - Jammu Links News
Does Keros Therapeutics Inc. stock perform well during market downturnsEarnings Report Growth Plan For Smart Trading - Jammu Links News
What is the risk reward ratio of investing in Keros Therapeutics Inc. stockTop Growth Tips For Consistent Profits - Jammu Links News
Corton Capital Inc. Invests $186,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (KROS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
Keros Therapeutics Inc (KROS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):